about
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needsPersonalized Medicine in AllergyMepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?Biosimilars in allergic diseases.New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic DiseasesThe path to personalized medicine in asthma.A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies.MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis.Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases.Current insights in allergen immunotherapy.Type 2 immunity in asthma.Strategies to reduce corticosteroid-related adverse events in asthmaThe North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trialsAnalysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real lifePharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatmentReduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuationA case of chronic eosinophilic pneumonia in a patient treated with dupilumabEvolving phenotypes to endotypes: is precision medicine achievable in asthma?New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologicDo the current guidelines for asthma pharmacotherapy encourage over-treatment?
P50
Q28067081-62D10265-1421-47FB-86F2-4F9C7354E11CQ28073074-5D3B230A-9192-4CA0-B459-2D1AFAAC9C03Q34544937-27D2BDCC-5F87-4788-8D12-D283139259FAQ38632790-DE70C036-60FE-4402-9075-086E2169654CQ38643541-1EA72BF4-2196-4050-91AA-2DF4CA98EFA7Q38834772-F5BE87E2-06D8-47FB-92AA-20951ED0DDBCQ38843261-B793C3DA-976F-459A-A5E2-0FFA10B45571Q38956459-993DA732-7C0D-455C-975E-776CC8064066Q39189229-004BD93F-1CD2-4B66-8C49-C57287FF310AQ39201543-0C39DEDF-3992-4C63-BA4F-AAAB96E6CC49Q39304288-5AA55239-A19A-4A03-BCE9-A82AA1E2034EQ39399204-F9472527-AD66-4E64-BEE8-28D5FFB01FA0Q42331967-2ED98144-0A8C-4F3B-83CD-0F650864E559Q50138857-2A0F7C39-AB29-4705-AF3F-9DDC24F8BCAFQ55454410-3F02494D-9D85-44C3-9A12-49B3FE5AEB58Q58606415-1986C421-E4AB-4B56-8A46-3DA2506E287DQ59791503-A7EC6E41-5CE4-470D-BB91-F4DC7958419CQ90825864-D8844210-D5FC-469B-8EC0-A611AF6B9F53Q90995749-DDF84C62-51D8-4F8D-8EE3-87FE3D9BB6EEQ91595370-2011C68D-7671-47E4-B383-9D40F901590DQ91970371-3CC10DD6-5049-4F55-AF56-BB951D09A229Q92354428-827B83E7-1986-4FBD-AF4D-C38D6B078584Q92403620-8852E5A6-F4EC-4691-B5BC-1450307022E7Q92696109-260047DE-4471-4CD9-928E-F6AACBF0532BQ94656248-FED25D56-CC8F-46C1-AFDA-46217529E516
P50
description
researcher ORCID ID = 0000-0002-3661-5731
@en
name
Diego Bagnasco
@ast
Diego Bagnasco
@en
Diego Bagnasco
@es
Diego Bagnasco
@nl
type
label
Diego Bagnasco
@ast
Diego Bagnasco
@en
Diego Bagnasco
@es
Diego Bagnasco
@nl
prefLabel
Diego Bagnasco
@ast
Diego Bagnasco
@en
Diego Bagnasco
@es
Diego Bagnasco
@nl
P1153
55256913800
P21
P31
P496
0000-0002-3661-5731